market access

News

NHS trumpets Hep C deal, quietly drops 2025 elimination targ...

NHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate hepatitis C from the country - although it has had to drop a 2025 target

News

NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay

NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.

Partner Content

$Banner for Media partners {460x250px}_3rd Antibody Bispecifics$

Partner Content

3rd Annual Antibody Summit: Bispecifics & Multispecifics

We are pleased to invite you to the 3rd Annual Antibody Summit: Biscpecifics & Multispecifics scheduled for May 15 - 16, 2019 in Vienna, Austria.

Partner Content

$Banner for Media partners {460x250px}_Gene and Cell Therapy$

Partner Content

Gene and Cell Therapy: Quality Developments to Commercializa...

We are pleased to invite you to the Annual Gene and Cell Therapy: Quality Developments to Commercialization Summit, scheduled for June 5-6, 2019, in Berlin, Germany.

Partner Content

$Banner for Media partners {460x250px}_3rd Aseptic Processing$

Partner Content

3rd Annual Aseptic Processing Summit

Vonlanthen Group is pleased to invite you to the 3rd Annual Aseptic Processing Summit scheduled on November 20-21, in Vienna, Austria.

Partner Content

$Banner for Media partners {460x250px}_4th Antibody Drug Conjugates$

Partner Content

4th Annual Antibody Drug Conjugates (ADC) Summit: From Targe...

We are pleased to invite you to the 4th Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 15-16, 2019 in Vienna, Austria.

NHS trumpets Hep C deal, quietly drops 2025 elimination targ...

NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay

3rd Annual Antibody Summit: Bispecifics & Multispecifics

Gene and Cell Therapy: Quality Developments to Commercializa...

3rd Annual Aseptic Processing Summit

4th Annual Antibody Drug Conjugates (ADC) Summit: From Targe...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

market access

Editor's Picks